VJHemOnc is committed to improving our service to you

SOHO Italy 2020 | Genetic profiling of multiple myeloma in the novel agents era

VJHemOnc is committed to improving our service to you

Niccolo Bolli

Niccolo Bolli, MD, PhD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, outlines the role of genetic profiling in multiple myeloma. Dr Bolli discusses the molecular heterogeneity of molecular myeloma and its importance in disease classification as well as precision medicine and highlights venetoclax, a BCL-2 inhibitor, which is effective in only a specific molecular subtype of multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter